This study aimed to evaluate the feasibility of combining helical tomotherapy (HT) and intensity-modulated proton therapy (IMPT) in treating patients with nasopharynx cancer (NPC). From January 2016 to March 2018, 98 patients received definitive radiation therapy (RT) with concurrent chemotherapy (CCRT). Using simultaneous integrated boost and adaptive re-plan, 3 different dose levels were prescribed: 68.4 Gy in 30 parts to gross tumor volume (GTV), 60 Gy in 30 parts to high-risk clinical target volume (CTV), and 36 Gy in 18 parts to low-risk CTV. In all patients, the initial 18 fractions were delivered by HT, and, after rival plan evaluation on the adaptive re-plan, the later 12 fractions were delivered either by HT in 63 patients (64.3%, HT only) or IMPT in 35 patients (35.7%, HT/IMPT combination), respectively. Propensity-score matching was conducted to control differences in patient characteristics. In all patients, grade ≥ 2 mucositis (69.8% vs 45.7%, P = .019) and grade ≥ 2 analgesic usage (54% vs 37.1%, P = .110) were found to be less frequent in HT/IMPT group. In matched patients, grade ≥ 2 mucositis were still less frequent numerically in HT/IMPT group (62.9% vs 45.7%, P = .150). In univariate analysis, stage IV disease and larger GTV volume were associated with increased grade ≥ 2 mucositis. There was no significant factor in multivariate analysis. With the median 14 month follow-up, locoregional and distant failures occurred in 9 (9.2%) and 12 (12.2%) patients without difference by RT modality. In conclusion, comparable early oncologic outcomes with more favorable acute toxicity profiles were achievable by HT/IMPT combination in treating NPC patients.
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| INTRODUC TI ON
Intensity-modulated radiation therapy (IMRT) has been the standard technique when treating most head and neck cancer (HNC) patients. 1, 2 Since 2011, when IMRT for HNC was first recognized as standard practice by the Korean National Health Insurance system, we began to use helical tomotherapy (HT) when treating HNC patients. 3 Our policy of definitive radiation therapy (RT) for loco-regionally advanced HNC, including nasopharynx cancer (NPC), was to deliver 30 fractions of HT with a simultaneous integrate boost (SIB), in which an adaptive re-plan was applied to accommodate body contour changes during the later 12 fractions, and concurrent administration of systemic therapy. 4, 5 Proton beam therapy (PBT), by virtue of Bragg-Peak, can frequently generate more favorable dosimetric profiles when compared with other up-to-date photon-based RT techniques, including IMRT, in many cancer types. 6 Although this involves higher cost for installation and operation of the PBT facility, PBT is known to offer promising cost-effectiveness when treating the most high-risk HNC patients, as targets are almost always closely surrounded by many critical normal structures. 7, 8 Our institute started the clinical operation of 2 rotating PBT gantries, both with intensity modulated proton therapy (IMPT) capability, in December 2015. 9 For HNC patients, there are some studies that reported that the longer the time between diagnosis and initiation of treatment, the worse oncologic outcomes would be. 10, 11 Because high demand for PBT outstripped the limited resources at our institute, the average waiting time before commencing PBT after therapeutic decision was around 4 wk or longer, while that for HT was usually up to a week.
To avoid this undesirable long waiting interval for PBT to start, we designed an alternative RT schedule to combine HT and IMPT: starting RT with HT to deliver an initial 18 fractions; and switching to IMPT during the later 12 fractions of the adapted re-plan. The current study assesses these early clinical outcomes in treating NPC patients, including acute toxicity profiles following combined HT and IMPT, compared with HT alone throughout the RT course.
| MATERIAL AND ME THODS

| Patients
From manual. 12 We retrospectively reviewed the medical records of these patients after Institutional Review Board approval (IRB No.
SMC 2018-01-116).
| Treatment scheme
Dose planning was generated twice in all patients: the first one for the initial 18 fractions; and the second one for the later 12 fractions from the adaptive re-plan, respectively. Three levels of target volume were manually contoured on the simulation CT images according to our institutional protocol. 4 
| Evaluation of acute side effects, response, and subsequent follow-up
During the RT course, all patients were examined weekly to evaluate acute toxicities and tumor response. Acute toxicities including oral mucositis, radiation dermatitis, and weight loss were graded according to Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.03. 13 In addition, analgesic usage during the RT course was evaluated according to the grading system that represented our pain control policy: grade 0 was defined as no need of analgesics; grade 1 was non-regular use of non-opioid analgesics only for 4 wk or shorter; grade 2 was regular use of nonopioid analgesics with or without intermittent local anesthetic 
| Statistical analysis
The chi-squared test or the Fisher's exact test for categorical variables and the independent t test for continuous variables were used 
| RE SULTS
| Patient characteristics
| Toxicities
The acute toxicity profiles are summarized in Table 2 and illustrated in Figure 2 . Among all patients, grade ≥ 2 dermatitis, mucositis, weight loss, and analgesic usage were observed in 65 (66.3%), 60 (61.2%), 50 (51.0%) and 47 patients (48.0%), respectively. Grade ≥ 2 mucositis was significantly less frequent in the HT/IMPT combination group (69.8% vs 45.7%, P = .019) (Figure 2A ). Grade ≥ 2 analgesic usage was also less frequent, although not significantly (54% vs 37.1%, P = .110). Numerically, grade ≥ 3 dermatitis was more frequent In univariate analyses of demographic-, clinical-, and treatmentrelated factors with toxicity profiles, grade ≥ 2 dermatitis was more frequent in patients of a younger age (P = .057) and more limited smoking history (86.8% vs 59.3%, P = .005). Grade ≥ 2 mucositis was more frequent in patients with stage IV disease (78.1% vs 52.7%, P = .051), and larger GTV volume (P = .010) ( Table 3) . Grade ≥ 2 weight loss was more frequent in patients with stage IV disease (62.8% vs 41.8%, P = .039), larger GTV volume (P = .004), and bilateral neck irradiation (53.2% vs 0%, P = .054). Grade ≥ 2 analgesic usage was more frequent in patients with larger GTV volume (P = .097). In multivariate analyses of the related factors with grade ≥ 2 mucositis, there were no significant factors including RT modality (HT only vs HT/IMPT combination), stages (I-III vs IV), and GTV volume (Table 3 ).
| Oncologic outcome
In 4 months after CCRT completion, the early response was excellent in both groups with an overall response rate and complete response rate of 100% and 84.7%, respectively. The median fol- 
| D ISCUSS I ON
PBT has widened the therapeutic window with the potential of saving more normal structures when treating HNC patients, when compared with other photon-based RT techniques. 7 Although there have been no prospective clinical trial data that directly compared IMPT and IMRT, there have been several dosimetric studies and retrospective reports. [15] [16] [17] [18] Lewis and colleagues 19 compared IMPT vs rival IMRT plans generated for 9 NPC patients who actually were treated with IMPT, and demonstrated significant lower doses to the normal tissues including the oral cavity using IMPT with similar conformality and homogeneity around the targets. Holliday and colleagues, 20 in a case-matched analysis of NPC patients who received either IMPT or IMRT, reported that the rate of feeding gastrostomy tube placement was significantly reduced following IMPT due to better sparing of the oral cavity mucosa. Although there are not much data on clinical efficacy, it is clear that dosimetric advantage appears to translate into improvements in acute toxicity profiles. 7 Higher clinical demand than PBT resources could accommodate, however, often necessitate an undesirable long delay before treatment initiation for PBT as the initial modality. This long delay was known to have reduced oncologic outcomes, 10,11 and may not be easily tolerated by many HNC patients and their families, together with the physicians in charge. Induction chemotherapy before IMPT initiation, to bridge the gap, could also be considered.
However, we would not recommend this approach, instead of upfront CCRT, based on 2 main reasons: first, no significant benefit of clinical outcomes; and second, increased risk of added morbidity and increased care cost. 21 We generated RT plans both for HT and IMPT for the several HNC patients for dosimetric comparison purpose, and achieved more favorable saving of oral cavity structures in most cases by combining HT and IMPT, when compared with HT only (Figure 1 for example) . Based on our dosimetric comparison results and to avoid any long delay, we decided to start RT using HT to deliver the initial 18 fractions and then switch to IMPT to deliver the later 12 fraction as the adaptive RT modality. The current study reports the early clinical outcomes, including acute toxicity profiles and response using this combination. Alhough we were not able to take full dosimetric advantage of IMPT throughout the RT course,
we were able to avoid too long a delay before treatment initiation. In addition, we achieved more favorable acute toxicity profiles, especially grade ≥ 2 mucositis following combined HT and IMPT, without undue waiting, when compared with HT only, although with no statistical significance. Based on our observations, we speculate that the greater potential benefit of less frequent and less severe toxicity profiles could be achieved by increasing the proportion of IMPT.
Moreover, we reduced the direct cost of RT by upto 28% according to the Korean National Health Insurance plan, when compared with the whole RT course of 30 fractions of IMPT. Considering the resource limitation and, at the same time, the potential benefits, we recently modified the dose schedule to deliver 67.2 Gy in 28 parts:
18 HT + 10 IMPT or 16 HT + 12 IMPT. In addition, the interval of concurrent chemotherapy (cisplatin) was optionally chosen between the 2 schedules (3-weekly vs weekly) considering the patients' conditions, which could reduce the acute side effects. These changes are expected to increase PBT utilization efficiency, to reduce the acute toxicity risk and deliver optimal overall treatment cost without altering therapeutic efficacy, as they possess a comparable biologically equivalent dose as the higher systemic therapy dose intensity.
The current study, mainly because of its retrospective nature, has the weakness of unequal distribution of patients with respect to AJCC stage and GTV volume. A propensity-score matching method was applied to overcome this innate selection bias. However, the relatively small sample size might still have masked the further potential benefits of combining HT and IMPT. In addition, the policy of selective neck irradiation with reduced elective radiation dose at our institution could have reduced oral cavity dose and led to decreased acute toxicities in all patients regardless of treatment group, when compared with previous studies. 5, 19 Decreased toxicities in all patient groups might also have masked further potential benefits of the HT/IMPT combination.
The current study, however, is believed to have a few strong points. First, we avoided the undesirable long waiting time before treatment initiation. Second, this is the first study to report the planned sequential combination HT and IMPT. In previous studies, PBT was mainly used as a boost technique following or simultaneously with photon therapy, [22] [23] [24] and also showed favorable toxicity and treatment results. Third, the acute toxicity profiles were, more or less, favorable following the HT/IMPT combination, while oncologic outcomes were all excellent and comparable. Fourth, we reduced the direct cost of RT by using the HT/IMPT combination, when compared with a whole course of IMPT. Longer term follow-up and recruiting more patients, or a prospective randomized clinical trial, however, would be needed to document the issues on late toxicities as well as long-term oncologic outcomes.
The current combination of HT and IMPT over the 6 wk RT course seemed feasible with respect to normal tissue sparing and avoidance of undesirable waiting times before treatment initiation.
Excellent and comparable early oncologic outcomes with more favorable acute toxicity profiles were achieved using the HT/IMPT combination. Further effort to develop a more optimum and cost-effective dose schedule may be warrantied.
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